

KAC ASTHMA REGISTRY DATA ELEMENT (APPOINTMENT)

IDENT	IFIER	
	<u></u>	mographic
1.	Socioue	mographic
	2	Age (years)
	a.	
		Gender (M/F) Sthmight (M/C/L/Othors)
	C.	Ethnicity (M/C/I/Others)
APPO	INTMENT	
2.	Date (D	DMMYY) e.g. 100324
3.	Type of	Clinic
	a.	Asthma clinic
	b.	Outpatient clinic
4.	Team-b	ased care provided (2 or more asthma care providers manage the patient)
		V
	a.	Yes
	b.	No
CLINIC	CAL ASSES	SSMENT
5.	Severe	exacerbation in the last one year requiring acute care.
	a.	No severe exacerbation
	a. b.	
		Emergency unit visit (no admission)
	C.	Hospital admission
	d.	Intubation or any assisted ventilation Unsure
	e.	Offsure
6.	GINA	ssessment of control
0.	UIIVA 6	issessment of control
	a.	Controlled
	b.	
	о. С.	Uncontrolled
	d.	Not done
	u.	Not done
7.	Averas	ge SABA used per week.
		,
	a.	< 1 time
	b.	1-2 times
	c.	3-9 times
	d.	10 and above (excessive use)
	e.	Unsure
	f.	Not Applicable
8.	PEFR a	ssessment performed
		v.
	a.	Yes
	b.	No











- c. (NA if not done)
- 9. Best PEFR reading today (L/min)

PHARMACOLOGICAL TREATMENT

- **10. Reliever** (*More than 1 option is allowed if more than 1 reliever is prescribed*)
 - a Salbutamol
 - b. Symbicort
 - c. Others (e.g., Atrovent, Berodual etc.)
 - d. No relievers
- **11. Preventer** (More than 1 option is allowed if more than 1 preventer is prescribed)
 - a. Inhaled corticosteroid (e.g. Budesonide, Fluticasone, Beclomethasone etc.)
 - b. LABA/ICS (e.g. Seretide, Symbicort etc.)
 - c. Oral corticosteroid
 - d. LAMA alone or LAMA/LABA combination (E.g., Ellipta, Seebri Breezehaler, Spiriva)
 - e. Leukotriene receptor antagonist (LTRA) (E.g., montelukast, Theophyllin)
 - f Others
 - g. No preventer prescribed
- **12. Reliever** (More than 1 option is allowed if more than 1 reliever is prescribed)
 - a. Salbutamol
 - b. Symbicort
 - c. Others (e.g., Atrovent, Berodual, etc.)
 - d. No relievers
- **13.** Adherence to preventer medication (*Take more than 80% of prescribed medication*)
 - a. Yes
 - b. No
- **14.** Duration of non-adherence to preventer medication (e.g., 2 weeks, 3 months, etc.)
- 15. Reason(s) of preventer medication default (More than 1 option allowed)
 - a. Forget
 - b. Interrupted supply
 - c. Misunderstanding
 - d. Not convinced
 - e. Other reasons
 - f. Not applicable
- 16. Inhaler technique taught or checked (including spacer if relevant)

(YES, if documented as done in the last ONE year and by any health provider)

- a. Yes
- b. No
- c. Not applicable (not on any inhaler)











17 .	Other management	more than	1 option allowed)
-------------	------------------	-----------	------------------	---

- a. Investigate and/or manage comorbidities (e.g., allergic rhinitis, smoking, obesity, etc.)
- b. Arrange investigations to confirm or revise diagnosis (e.g., spirometry etc.)
- c. Refer to medical/respiratory outpatient clinic
- d. None of above

ASTHMA ACTION PLAN	(YES	, i	f AAP is o	documented	as	done ir	the	last	ONE	vear
---------------------------	------	-----	------------	------------	----	---------	-----	------	-----	------

- 18. Asthma Action Plan (AAP) explained/revisited
 - Yes a.
 - No b.

ASTHMA EDUCATION (YES, for any items documented as done by any health provider in the last ONE year)

- 19. Asthma education: What is asthma (pathophysiology, signs and symptoms)
 - a. Yes
 - b. No
- 20. Asthma education: Asthma control (patient's current control and target asthma control)
 - a. Yes
 - b. No
- **21. Asthma education: Asthma medication** (*e.g.*, *correct inhaler*, *dosage*, *time*, *frequency*, *etc.*)
 - Yes a.
 - b. No
- **22. Asthma education: Triggering factors** (including significant allergy history)
 - Yes a.
 - b. No

FOLLOW UP

23. Duration of next appointment (e.g., 2 weeks, 3 months, etc.)









